Hims & Hers (HIMS) Soars 16% on Bullish Analyst Outlook

We recently published 10 Stocks With Eye-Popping Double-Digit Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the biggest performers on Wednesday.

Hims & Hers rallied for a second day on Wednesday, adding 16.02 percent to close at $58.02 apiece as investors took path from an investment firm’s bullish outlook and rating for the company.

In a market note on Wednesday, Zacks Research gave Hims & Hers Health, Inc. (NYSE:HIMS) a “strong buy” recommendation on expectations that its 2025 earnings per share will improve by 177.8 percent year-on-year.

Zacks also underscored Hims & Hers Health, Inc.’s (NYSE:HIMS) expansion program with the recent acquisition of ZAVA, a European digital health platform operating in the UK, Germany, France, and Ireland.

“This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA’s in-house medical team,” Zacks noted.

“The integration of ZAVA’s technology with Hims & Hers’ established brand positions it to deliver personalized, seamless digital healthcare across key European markets,” it added.

According to Hims & Hers Health, Inc. (NYSE:HIMS), it is scheduled to announce the results of its April-June earnings performance after market close on August 4.

While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.